The DOI matches its Crossref record; 83 of the 85 references it cites were found in a registry or an index, and 2 are not checked yet; 133 of the 242 sources its claims cite were checked for support.
The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review
Open accessAbstract
BACKGROUND: Retinal disease is one of the leading causes of blindness and vision impairment worldwide, including Europe. With the advent of gene therapy, the treatment landscape for retinal disease is changing and clinical trials are underway investigating the therapeutic potential of gene therapy in both acquired and inherited retinal diseases. Given the high price of innovative medicines, it is essential to consider the current costs associated with retinal diseases to inform economic evaluations early in the life cycle of these forthcoming treatments. These could inform future reimbursement decisions, health budgets and service delivery plans. AIM: This systematic literature review sought to examine the economic burden of retinal diseases, for which gene therapy is emerging for patients in Europe. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guideline, a systematic search was performed using the Medline, CINAHL, EconLit and Embase databases. The searches were restricted to English language articles published after 1st January 2000. Following article selection, data were extracted in a tabular form and a narrative synthesis was performed. RESULTS: A total of 28 research studies were identified and included in the review that varied in terms of disease of interest, size, country setting, methodology, as well as how costs were reported and valued. While many retinal diseases were considered, almost half of the articles related to the costs of neovascular age-related macular degeneration (nAMD). Significant cost variations were observed across the studies as costs ranged from 45 USD to almost 30,000 USD per patient per annum, across all conditions combined. CONCLUSION: This systematic literature review evidences the heterogeneity among studies analysing the economics of retinal diseases underlying vision impairment. The paucity in the literature, signals the need for further research investigating the costs associated with retinal diseases, for which innovative therapies are expected to enter the market and will be subject to evaluation by decision-makers, whose decisions will have a significant impact on the delivery of these technologies to patients.
Verified 2026-10-05 · 2 references not checked yet
Overview
CoChat Summary
TL;DR
This systematic review identified 28 European studies on the economic burden of retinal diseases for which gene therapy is emerging, finding wide cost variation and substantial methodological heterogeneity. It concludes that evidence is sparse and often outdated, limiting economic evaluations of forthcoming gene therapies.
Key findings
- The review included 28 studies; over half related to AMD (55%), followed by DR and DMO (31%), with RVO, mCNV and IRD combined accounting for 14%. Almost half of the articles related to nAMD.
- Annual per-patient costs ranged from $45 to almost $30,000 across all conditions. Ranges were higher in nAMD ($228–$28,000) and DMO ($370–$28,000) than in dry AMD ($300–$3,000), DR without complications ($45–$4,000), and macular oedema secondary to RVO ($1,800–$12,000).
- Direct medical costs were $228–$12,133 per patient per annum for nAMD and $370–$14,642 for DMO at patient level; NPDR direct medical costs were $45–$613 and PDR costs $441–$3,031.
- Only one IRD study and one mCNV study were identified. The IRD study reported direct medical costs of $674 and direct non-medical costs of $241 per patient per year; the mCNV study reported direct medical costs of $3,859, direct non-medical costs of $498, and productivity loss of $7,976 per patient per annum.
Methods
- PRISMA 2020 systematic review, registered in PROSPERO (CRD42024576511). Medline, CINAHL, EconLit and Embase were searched on 15 July 2024, restricted to English-language articles published after 1 January 2000 and studies conducted in the European region.
- Inclusion was limited to partial economic evaluations (cost analyses and cost-of-illness studies); full economic evaluations, reviews, conference presentations, case reports, protocols and abstracts were excluded. From 5,270 initial records, 3,169 were screened after duplicates, 301 underwent full-text screening, and 28 met inclusion criteria.
- Data were extracted in tabular form and narratively synthesised. Costs were inflated and converted to 2024 USD using the CCEMG–EPPI Centre Cost Converter; reporting quality was assessed with the British Medical Journal checklist for economic submissions and the CHEERS checklist.
Limitations
- Stated by the authors: the geographical scope was restricted to Europe; patients were not distinguished by disease severity or laterality; overrepresentation of nAMD studies may have made retinal disease costs appear higher than they are; and the effects of differences between older-age diseases (e.g. AMD) and younger-onset diseases (e.g. DR and IRD) on costs were not examined.
- Evident from the text: studies varied widely in disease of interest, sample size, country, methodology, cost components, perspective, time horizon, and how costs were reported and valued. Many nAMD studies used pre-2010 cost data and did not include anti-VEGF costs, so estimates may not reflect current practice.
- Evident from the text: indirect costs were estimated in only 10 studies, informal care in 3, and intangible costs in 2; non-ophthalmological and non-medical resources were inconsistently included, potentially underestimating the true economic burden.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







![Fig. 8 Total annual costs per person for macular oedema secondary to RVO and mCNV across countries (in 2024 USD). a RVO. RVO: retinal vein occlusion. b mCNV. mCNV: myopic choroidal neovascularisation]](https://figures.cochat.ai/paper-figures/ec697cbb0a154df79ec9a6666d8f2266/the-economic-impact-of-retinal-diseases-for-which-gene-therapy-is-emerging-a-figure-8.jpg)
Verification
Claims the paper makes
70 Valid · 6 Not valid · 31 Not checked · 56 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Annual productivity loss in patients ranged from $23 to $1,006 [34, 39].”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Results > Cost analysis
What the sources say
- Disputedcites [34] Abraldes MJ, Calvo P, Gámez Lechuga M, Merino M, Martín Lorenzo T, Maravilla-Herrera P, et al. Burden of disease study of patients with neovascular Age-Related macular degeneration in Spain. Ophthalmol Ther. 2024;13(7):1925–35. https://doi.org/10.1007/s40123-024-00960-9 sourceExperimental — accuracy not yet measured
The Results (Table 7; page not provided) report annual labor productivity losses of €17.9, €12.0, and €9.0 per patient across the three treatment-year groups. These figures do not support the claimed range of $23 to $1,006; the paper reports a much smaller maximum. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [39] Ke KM. The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration. Eur J Health Econ. 2010;11(6):525-31. https://doi.org/10.1007/s10198-009-0207-9. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“As for direct non-medical costs, reflecting the use of formal care, transportation and vision aids, they were estimated at $2,068 per patient per annum in the Spanish model-based study [55].”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Results > Cost analysis
What the sources say
- Disputedcites [55] Ruiz-Moreno JM, Gámez Lechuga M, Calvo P, Merino M, Martín Lorenzo T, Maravilla-Herrera P, et al. Burden of disease study of patients with diabetic macular oedema in Spain. Ophthalmol Ther. 2024;13(7):1937–53. https://doi.org/10.1007/s40123-024-00959-2. sourceExperimental — accuracy not yet measured
The Results report €1,358.0 per patient for direct non-healthcare costs in year 1, with lower costs in subsequent years—not $2,068 per patient annually. The Methods > Cost Items section supports the listed categories of formal care, travel and technical aids, but also includes informal care. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The review identified 28 studies that varied in terms of disease of interest, sample size, methodology, as well as how costs were reported and valued, thus concurring with previous literature that found a high degree of heterogeneity across these types of studies [17, 21–23].”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Discussion
What the sources say
- Disputedcites [17] Ng QX, Ong C, Yaow CYL, Chan HW, Thumboo J, Wang Y, et al. Cost-of-illness studies of inherited retinal diseases: a systematic review. Orphanet J Rare Dis. 2024;19(1):93. https://doi.org/10.1186/s13023-024-03099-9. sourceExperimental — accuracy not yet measured
The Results section says the review analyzed 9 articles, not 28. The Methods and Discussion describe differences in study design and costs, but that does not support the claimed study count. No page numbers are available in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [21] Köberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471. https://doi.org/10.1136/bmjopen-2013-003471. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the reviewed studies differed in methodology, sample populations, outcomes, and definitions of cost components; the Results likewise describe considerable variability in obtaining and reporting costs. The passages do not establish that the review identified 28 studies: the Results instead say that 17 of 22 studies dealing with direct or indirect costs met the quality threshold and were included. (LLM, conf=0.82)
- Partly supportedcites [22] Marques AP, Ramke J, Cairns J, Butt T, Zhang JH, Jones I, et al. The economics of vision impairment and its leading causes: a systematic review. eClinicalMedicine. 2022:46:101354. https://doi.org/10.1016/j.eclinm.2022.101354. sourceExperimental — accuracy not yet measured
The Results (Study design and Review results; page not provided) identify 138 included studies, not 28; 28 were cost-analysis studies. The Discussion (page not provided) describes substantial methodological heterogeneity, supporting the claim of variation but not its study count. (LLM, conf=0.90)
- Partly supportedcites [23] Benhamza M, Dahlui M, Said MA. Determining direct, indirect healthcare and social costs for diabetic retinopathy management: a systematic review. BMC Ophthalmol. 2024;24(1):424. Available from: http://www.ncbi.nlm.nih.gov/pubmed/39350064. sourceExperimental — accuracy not yet measured
The Results section says the review analyzed 13 articles, not 28. The Data extraction and synthesis section supports the broader point that the studies differed in participants, methodology, and cost measurement and analysis. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Discussion
What the sources say
- Disputedcites [47] Chakravarthy U, Bailey CC, Scanlon PH, McKibbin M, Khan RS, Mahmood S, et al. Direct ophthalmic healthcare resource use among patients with geographic atrophy in a large cohort from the United Kingdom. Ophthalmol Retina. 2019;3(11):920-926. https://doi.org/10.1016/j.oret.2019.06.012. sourceExperimental — accuracy not yet measured
The Results section (“Direct Ophthalmology-Related Visits and Costs”; page not available in our copy) reports separate monitoring costs for patients with bilateral geographic atrophy, geographic atrophy with neovascularization in the fellow eye, geographic atrophy with early/intermediate AMD in the fellow eye, and bilateral early/intermediate AMD. This contradicts the claim that this study did not distinguish costs across conditions. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Supportedcites [48] Ruiz-Moreno JM, Arias L, Abraldes MJ, Montero J, Udaondo P. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. Int Ophthalmol. 2021;41(10):3427-36. https://doi.org/10.1007/s10792-021-01906-x. source
The Methods > Costs section (page unavailable) says the study calculated overall direct healthcare costs and mean cost per patient for its AMD cohort. The Results table breaks costs down by resource and treatment, not by different conditions. This supports including RAMDEBURS as one of the cited studies; it does not establish the count of eight on its own. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [49] Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, Berdeaux G. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ. 2002;3(2):94-102. https://doi.org/10.1007/s10198-002-0104-y. source
- Supportedcites [50] Hertzberg SNW, Jørstad ØK, Petrovski BÉ, Bragadottir R, Steffensen LA, Moe MC, et al. Transition from laser to intravitreal injections for diabetic retinopathy: hospital utilization and costs from an extended healthcare perspective. Int J Environ Res Public Health. 2022;19(19):12603. https://doi.org/10.3390/ijerph191912603. source
This paper supports its inclusion among the cited studies: Methods §2.1 says the same ICD-10 code was used for proliferative diabetic retinopathy and diabetic macular edema, so treatments for the two conditions could not be separated. Methods §2.2 describes the study’s treatment-cost calculations. The count of eight studies is the citing authors’ characterization of the group, not a finding attributed to this individual paper. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [51] Kähm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41(5):971-978. https://doi.org/10.2337/dc17-1763. source
- Disputedcites [52] Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LÅ. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53(10):2147-54. https://doi.org/10.1007/s00125-010-1836-3. sourceExperimental — accuracy not yet measured
The Cost estimates section says the study estimated costs separately for four diabetic-retinopathy severity levels. Table 3 and the Discussion report distinct costs for background retinopathy, proliferative retinopathy, maculopathy, and their combination. Thus, this cited study did distinguish costs among the conditions it examined; our copy cannot establish what the other seven studies did. Page numbers were not available in our copy. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [53] Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J. The economic burden of diabetic retinopathy in Germany in 2002. Graefe’s Archive Clin Experimental Ophthalmol. 2008;246(1):151-9. https://doi.org/10.1007/s00417-007-0573-x source
- Disputedcites [59] Kessel L, Kjellberg J, Ibsen R, Rasmussen A, Nissen KR, la Cour M. Longitudinal analysis of health care costs in patients with childhood onset inherited retinal dystrophies compared to healthy controls. BMC Ophthalmol. 2022;22(1):466. https://doi.org/10.1186/s12886-022-02708-0. sourceExperimental — accuracy not yet measured
The Results (Table 1; page unavailable in our copy) distinguish outpatient and inpatient costs for eye care, injuries, and all other care, rather than reporting only undifferentiated costs. The paper does group other conditions together, but the unqualified claim that it did not distinguish costs of different conditions is contrary to those tables. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous literature reviews analysing costs associated with vision impairment and blindness found a high degree of heterogeneity across these studies in terms of size, methodology, as well as the way in which costs were defined and reported [17, 21–23].”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Background
What the sources say
- Partly supportedcites [17] Ng QX, Ong C, Yaow CYL, Chan HW, Thumboo J, Wang Y, et al. Cost-of-illness studies of inherited retinal diseases: a systematic review. Orphanet J Rare Dis. 2024;19(1):93. https://doi.org/10.1186/s13023-024-03099-9. sourceExperimental — accuracy not yet measured
The Results table shows differing study sizes, and the Discussion describes differences in data sources, methods, and which costs the reviewed studies included. However, this review covers costs of inherited retinal diseases specifically; it does not establish the claim for literature reviews of vision impairment and blindness more broadly. The indexed passages have no page numbers. (LLM, conf=0.84)
- Supportedcites [21] Köberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471. https://doi.org/10.1136/bmjopen-2013-003471. source
The Discussion (page not provided) says that no two reviewed studies used the same methodology or sample population and that they lacked standardized definitions of cost components. The Results (page not provided) highlight considerable variability in how costs were obtained and reported; Table 1 also shows differing study designs and sample sizes. (LLM, conf=0.88)
- Partly supportedcites [22] Marques AP, Ramke J, Cairns J, Butt T, Zhang JH, Jones I, et al. The economics of vision impairment and its leading causes: a systematic review. eClinicalMedicine. 2022:46:101354. https://doi.org/10.1016/j.eclinm.2022.101354. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports substantial methodological heterogeneity and considerable variation in how cost components were included and reported. The Results also show differences in study design and cost-estimation approach. Our copy does not establish the claimed heterogeneity in study size. (LLM, conf=0.83)
- Supportedcites [23] Benhamza M, Dahlui M, Said MA. Determining direct, indirect healthcare and social costs for diabetic retinopathy management: a systematic review. BMC Ophthalmol. 2024;24(1):424. Available from: http://www.ncbi.nlm.nih.gov/pubmed/39350064. source
The Methods and materials > Data extraction and synthesis passage (page unavailable) explicitly describes heterogeneity in study participants, settings, cost types, measurement, and analysis. The Results > Risk of bias passage (page unavailable) also shows differing classifications and cost labels. The review focuses on diabetic retinopathy, including studies of visual disorders, so it supports the cited point as an example of heterogeneity in this area. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
70 more claims · 34 with their cited sources checked
Create a free account to see all 163 claims and to verify the 3 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 40
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Discussion
“Of note, three out of the nine studies that included anti-VEGF costs were model-based [34, 54, 55]”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Results > Cost analysis
“While four out of the six studies were model based with a top-down approach to resource quantification [54–56, 58]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Results > Cost analysis
“Direct medical costs were estimated in all studies, followed by indirect costs in two Spanish studies [57, 61] and direct non-medical costs in the multi-county study [57].”
§ The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review > Results > Cost analysis
“Two of these were Spanish [57, 61] and one covered multiple countries (Germany France and Italy) [60].”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189 · cited 1×
“Retinal diseases, such as age-related macular degeneration (AMD), are one of the main contributors to the prevalence of blindness in adults over 50 [2, 3].”
The Lancet Global Health Commission on Global Eye Health: vision beyond 2020
Burton, M. J., Ramke, J., Marques, A. P., Bourne, R. R. A., Congdon, N., Jones, I., Ah Tong, B. A. M., Arunga, S., Bachani, D., Bascaran, C., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30488-5 · Cited by 1,624 · cited 1×
“In Europe alone, around 50 million individuals are affected by vision loss [1].”
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.10.008 · Cited by 847 · cited 1×
“Both the British Medical Journal Checklist for economic submissions, geared towards COI studies [31, 32] and the Consolidated Health Economic Evaluation Reporting Standard (CHEERS) checklist [33] were used to assess the reporting quality of the results.”
Cost-of-illness studies: concepts, scopes, and methods
Jo, C. (2014) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2014.20.4.327 · Cited by 800 · cited 2×
“In ophthalmology, as in other disease areas, the research reflects three main categories of costs, including direct (medical and non-medical), indirect and intangible costs [22, 27–29].”
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703 · cited 2×
“Furthermore, diabetic retinopathy (DR), a complication of diabetes mellitus, is one of the leading causes of blindness amongst the working age population [4, 5].”
Liew, G., Michaelides, M., & Bunce, C. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004015 · Cited by 663
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639 · cited 1×
“…have revolutionized the treatment landscape for patients in Europe with a range of retinal diseases, including nAMD, diabetic macular oedema (DMO) (a potential complication of DR), as well as macular oedema due to retinal vein occlusion (RVO) and myopic choroidal neovascularisation (mCNV) [4, 7–9].”
Lakdawalla, D. N., Doshi, J. A., Garrison, L. P., Phelps, C. E., Basu, A., & Danzon, P. M. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.007 · Cited by 540 · cited 1×
“Some argue that other factors may also contribute to the value of ATMPs to patients and society include hope, an unmet need addressed, perceived inno-vativeness and the intervention’s propensity to transform the lives of patients and their carers [78, 85–87].”
A web-based tool for adjusting costs to a specific target currency and price year
Shemilt, I., James, T., & Marcello, M. (2010) · Evidence & Policy · doi:10.1332/174426410x482999 · Cited by 411 · cited 1×
“Given the heterogeneity between studies in terms of currencies and time periods, costs were inflated and converted to 2024 USD values, using the CCEMG–EPPI Centre Cost Converter web-based tool [30].”
Research works printed but not linked: 2
- Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, Second Edition. American J Prev Med. 1998;14.
- European Commission. European Commission-Press release New EU rules on Health Technology Assessment open up a new era for patient access to innovation. 2025.
Metadata
- Authors
- Willmington, C., Kirby, A., & Murphy, A.
- Affiliations
- University College Cork (IE)
- Corresponding author
- Willmington, Claire
- Venue
- Health Economics Review
- Published
- 2025-12-07
- Volume
- 16
- Issue
- 1
- Pages
- 21-21
- ISSN
- 2191-1991 (ISSN-L)
- PMC
- PMC12922378
- OpenAlex
- W4417115362
- Semantic Scholar
- 4567cbc5bec9efaa95ef616f38d222e29de9da5a
- Cited by
- 0
- References
- 83
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 74 d)
- Locations
- Health Economics Review (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Union’s Horizon Europe (101073316)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- retinal disease, gene therapy, economic burden, health care costs, neovascular age-related macular degeneration, inherited retinal disease, visual impairment, cost heterogeneity, reimbursement decisions, innovative medicines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review. https://app.cochat.ai/papers/10.1186/s13561-025-00707-7
- The paper
- Willmington, C., Kirby, A., & Murphy, A. (2025). The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review. Health Economics Review. https://doi.org/10.1186/s13561-025-00707-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.